The Vanguard Group, Inc. Discloses Position in Life Science REIT plc

The Vanguard Group, Inc. has issued a Form 8.3 disclosure concerning its positions in Life Science REIT plc. The document, dated March 24, 2026, indicates that Vanguard holds 3,284,952 ordinary shares, representing 0.94% of the securities. An additional disclosure mentions British Land Company plc.

The group reported a sale of 5,632 ordinary shares at 0.39 GBP per unit. No cash-settled or stock-settled derivatives have been disclosed, and there are no indemnity or option arrangements noted in the report. No agreements regarding voting rights or future acquisitions exist.

Shawn Acker is the contact for this disclosure. The Vanguard Group, Inc. has not attached a Supplemental Form 8 for open positions. This public disclosure adheres to Rule 8.3 of the Takeover Code.